TABLE 4.
Association of SNP genotypes with tacrolimus C0/D.
6th day | 6 months | 1 year | |||||||
---|---|---|---|---|---|---|---|---|---|
Gene/genotype | n | C0/D | p value | n | C0/D | p value | n | C0/D | p value |
CYP3A5*3 | |||||||||
*3/*3 | 50 | 145.45 ± 54.99 | <0.001 a | 43 | 163.06 ± 74.29 | <0.001 a | 32 | 176.1 ± 64.65 | <0.001 a |
*1/*3 | 33 | 77.1 ± 38.43 | 38 | 107.38 ± 50.61 | 28 | 114.07 ± 57.21 | |||
*1/*1 | 9 | 66.46 ± 36.09 | 8 | 87.18 ± 53.18 | 6 | 62.38 ± 33.75 | |||
CYP3A5 Non-expressor | 50 | 145.45 ± 54.99 | <0.001 a | 43 | 163.06 ± 74.29 | <0.001 a | 32 | 176.1 ± 64.65 | <0.001 a |
CYP3A5 Expressor | 42 | 74.82 ± 37.77 | 46 | 103.87 ± 51.04 | 28 | 104.95 ± 57.01 | |||
CYP3A4*1G | |||||||||
*1/*1 | 39 | 146.11 ± 58.02 | <0.001 a | 33 | 168.89 ± 72.7 | <0.001 a | 26 | 180.48 ± 63.39 | <0.001 a |
*1/*1G | 38 | 92.65 ± 49.31 | 41 | 109.5 ± 58.99 | 31 | 121.37 ± 60.75 | |||
*1G/*1G | 13 | 72.02 ± 38.72 | 13 | 108.25 ± 55.88 | 8 | 66.21 ± 29.39 | |||
CYP3A4*1B | |||||||||
AA | 80 | 117.36 ± 60.12 | 0.048 a | 81 | 132.12 ± 71.19 | 0.972 | 63 | 137.28 ± 70.85 | 0.472 |
AG | 9 | 75.87 ± 44.56 | 5 | 133.26 ± 55.7 | 1 | 189 | |||
ABCB1 C3435T | |||||||||
CC | 10 | 142.57 ± 71.69 | 0.193 | 12 | 125.08 ± 79.03 | 0.73 | 11 | 106.66 ± 56.38 | 0.216 |
CT | 38 | 115.5 ± 54.5 | 33 | 140.33 ± 72.36 | 23 | 151.03 ± 69.46 | |||
TT | 43 | 104.97 ± 60.14 | 43 | 129.2 ± 66.65 | 32 | 142.39 ± 73.43 | |||
ABCB1 G2677T | |||||||||
GG | 8 | 147.86 ± 71.44 | 0.219 | 10 | 149.08 ± 75.37 | 0.706 | 8 | 133.32 ± 60.61 | 0.727 |
GT | 42 | 107.75 ± 55.52 | 35 | 127.95 ± 74.06 | 28 | 146.16 ± 72.68 | |||
TT | 39 | 111.87 ± 61.19 | 41 | 131.69 ± 66.48 | 28 | 131.38 ± 72.58 |
Statistically significant.